VISTN Vistin Pharma ASA

Vistin Pharma ASA: Invitation to Q2 2024 conference call

Vistin Pharma ASA: Invitation to Q2 2024 conference call

Oslo, Norway, 16 August 2024

Vistin Pharma ASA will release its second quarter and YTD 2024 results on Friday 23rd of August 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 23rd of August at 08:30 CET. There will be a Q&A session following the management discussion.

The conference call will be held in English.

The second quarter conference call will be available via web and audio through the following access points:

Webcast:

Telephone conference (online registration):

*****

For further information, please contact:

Alexander Karlsen

CFO





About Vistin Pharma |

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.

 





EN
16/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE

Ex dividend NOK 0.50 today

Ex dividend NOK 0.50 today The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.50 as from today, 06.11.2024.

 PRESS RELEASE

Vistin Pharma ASA: Third quarter and YTD 2024 financial results

Vistin Pharma ASA: Third quarter and YTD 2024 financial results Oslo, Norway, 31st of October 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2024. Revenue in the third quarter ended at MNOK 106 compared to MNOK 120 in Q3 2023. Sales volume in the quarter decreased compared to same quarter last year driven by lower sales volume, safety stock build and lower global Metformin prices. Revenue for first nine months of 2024 ended at MNOK 316 compared to MNOK 328 YTD last year. Third quarter EBITDA ended at record high MNOK 29 compared to MNOK 2...

 PRESS RELEASE

Vistin Pharma ASA: Invitation to Q3 2024 conference call

Vistin Pharma ASA: Invitation to Q3 2024 conference call Oslo, Norway, 24 October 2024 Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Thursday 31st of October at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The third quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online reg...

 PRESS RELEASE

Responsibility statement for first half year of 2024

Responsibility statement for first half year of 2024 Please find attached the first half 2024 financial report including the Responsibility Statement. ***** For further information, please contact: Alexander KarlsenCFO This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment

 PRESS RELEASE

Vistin Pharma ASA: Mandatory notification of trade

Vistin Pharma ASA: Mandatory notification of trade Saga Pure ASA has on 26 September 2024 purchased 50,000 shares in Vistin Pharma ASA at NOK 28.2 per share. After the transaction Saga Pure ASA has a holding of 700,000 shares, corresponding to 1.58% ownership.Saga Pure ASA is closely associated with board member Øystein Stray Spetalen.   This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch